Menu
Search
|

Menu

Close
X

Citius Pharmaceuticals Inc CTXR.OQ (NASDAQ Stock Exchange Capital Market)

1.61 USD
-- (--)
As of Oct 22
chart
Previous Close 1.61
Open --
Volume --
3m Avg Volume 37,251
Today’s High --
Today’s Low --
52 Week High 5.46
52 Week Low 1.12
Shares Outstanding (mil) 16.20
Market Capitalization (mil) 28.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.009
FY17
-1.931
FY16
-2.159
FY15
-1.363
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
--
6.55
Price to Book (MRQ)
vs sector
0.88
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.80
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-76.64
12.83
Return on Equity (TTM)
vs sector
-76.64
14.95

EXECUTIVE LEADERSHIP

Leonard Mazur
Executive Chairman of the Board, Secretary, Since 2016
Salary: $250,000.00
Bonus: $120,000.00
Myron Holubiak
President, Chief Executive Officer, Director, Since 2016
Salary: $225,000.00
Bonus: $112,500.00
Jaime Bartushak
Chief Financial Officer, Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Suren Dutia
Director, Since 2015
Salary: --
Bonus: --
Eugene Holuka
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11 Commerce Dr Fl 1
CRANFORD   NJ   07016-3501

Phone: +1908.9676677

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

SPONSORED STORIES